Skip to main content
. 2014 Oct 30;6(6):1560–1570. doi: 10.4161/19420862.2014.975099

Figure 1.

Figure 1.

Increasing the valency of DR5 binding domains results in more potent agonists than APO2L/TRAIL or conventional antibody agonist. (A) Diagramatic representation of DR5 Nanobody molecules compared to antibodies. (B) Binding of multivalent DR5Nb1 to COLO 205 cells by flow cytometry (ΔMFI, change in mean fluorescence intensity). Viability of (C) COLO 205, (D) MIA PaCa-2 and (E) BxPC-3 cells treated with indicated concentrations of DR5Nb1-tri, DR5Nb1-tetra, DR5Nb1-penta, APO2L/TRAIL or x-LBY135. Viability of Cells were assessed by CellTiterGlo (Promega).